BEAM
Beam Therapeutics Inc.

Beam Therapeutics Inc.BEAM

Healthcare · Biotechnology
24.90USD
+4.67%
Oct 28, 2026
BEAM overview ready
Clinical-Stage Developer Advancing Base-Edited Genetic Medicines for Rare Diseases
Beam is a clinical-stage, platform-focused developer of base-edited genetic medicines across ex vivo hematology and in vivo liver-targeted rare-disease programs.
Narrative is still early
Exposed to the Precision Genetic Medicine Commercialization narrative through Therapeutic Genome Editing for Monogenic Disease — pure play.
Price trend is broken
Longer-term context reads damaged structure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
Demanding valuation
The price embeds expectations that run ahead of the growth it delivers per turn of revenue multiple.
Unremarkable fundamentals
Primary risk
Clinical trial and regulatory approval risk.
Market Oct 27Filing Jun 30Price action Aug 2Research Aug 2

Conviction Level

CompanyFit8.0PriceAction2.0Valuation3.2CompanyPosition9.3BusinessQuality—

Conviction uses Company Fit, Price Action, Valuation, Business Quality. Company Position is research context, not an input.

Theme leadershipGroup context · not a Conviction input
Gene Editing is tracked (too few stocks) — no leadership reading
Price
Loading price history…

Price Action

Price trend is broken
Longer-term context reads damaged structure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.

Key Financials

Market Cap
$2.6B
Avg Volume (60D)
1.8M
60 sessions
Revenue Growth YoY
+120.0%
FY2025 vs FY2024
Gross Margin
-161.9%
Operating Margin
-242.3%
Trailing twelve months
Free Cash Flow Yield
-14.5%
P/E
N/M
EV / Sales
9.7x
Market metrics as of Oct 27, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026

Fundamentals & Valuation

The available comparisons disagreed; the intrinsic comparison is the more reliable method for this business and the others are published as dissent.
Beam Therapeutics Inc. has an Expensive valuation stance because the price embeds expectations that run ahead of the growth it delivers per turn of revenue multiple.

Company Research

Thesis
Beam is a clinical-stage, platform-focused developer of base-edited genetic medicines across ex vivo hematology and in vivo liver-targeted rare-disease programs. BEAM is a direct, high-beta pure play on therapeutic genome editing rather than merely an adjacent biotech participant.
Opportunity
Moderate opportunity
Clinical and regulatory progress toward one-time, potentially durable gene-editing treatments that address the genetic root cause of inherited diseases.
Key risk
Clinical trial and regulatory approval risk.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Biotechnology
What they do

Beam Therapeutics develops precision genetic medicines using base editing technology to create therapies for serious diseases, primarily focusing on hematology and genetic disorders.

How it earns

The company generates revenue primarily through project-based collaborations and future product sales upon regulatory approval.

Products & services
Ristoglogene autogetemcel (autologous hematopoietic stem cell therapy for sickle cell disease)
BEAM-302 (liver-targeting lipid nanoparticle for alpha-1 antitrypsin deficiency)
BEAM-304 (liver-targeting lipid nanoparticle for phenylketonuria)
BEAM-301 (liver-targeting lipid nanoparticle therapy)
Customers & end markets
Patients with serious genetic and hematologic diseases in the United States
Healthcare providers and research collaborators in biotechnology and medicine
Market position

Niche player focused on precision base editing therapies within the biotechnology sector.

Demand drivers
Low cyclicality

Demand is driven by medical need and regulatory progress rather than economic cycles.